Therefore, the reduction in STAT3 by SA14 overexpression may also alleviate MSH in tumour cells and reduce the accumulation of neoantigens, which might blunt the antitumour effect of anti‐PD‐L1 immunotherapy. This evidence concerns the gene STAT3 and neoplasm.